“…In this context, starting from a structurally-related NAMI-A analog, called AziRu (Figure 1a) [36,37], we previously designed and synthesized a library of highly functionalized nucleolipid- [29,38] or aminoacyl lipid-based [39] Ru(III)-containing complexes. The resulting derivatives have been then co-formulated with biocompatible vesicle-forming Molecules 2023, 28, 5775 2 of 12 lipids, such as POPC or DOTAP, obtaining a mini-library of various Ru(III)-loaded liposomes [29,36,40,41] characterized by high antiproliferative activity on human cancer cells, especially of breast cancer origin, and no relevant toxicity on control healthy cell lines [29,42]. These liposomes also proved to be effective and selective in vivo in preclinical evaluation studies in suitable breast cancer xenografts mouse models [43,44].…”